#445 DIGEST-Hotcakes: Preventive PCI, Andexanet Alfa for ICH, Aspirin for Fatty Liver, Naltrexone in Cirrhosis, Pivmecillinam for UTI, Cefepime vs Pip-Tazo, MDRO Decolonization, Microplastics and MACE, Pax-NO-vid
The Curbsiders Internal Medicine Podcast
00:00
Evaluation of Preventive PCI in the PREVENT Trial
The chapter discusses the PREVENT trial, which compares the effectiveness of optimal medical therapy with PCI to optimal medical therapy alone for high-risk vulnerable plaques. It examines the trial's outcomes over two, four, and seven years of follow-up and highlights concerns about bias and the impact of industry funding on the results. The chapter also touches on the Anexa I trial, which evaluated the use of andexanet alpha for patients with DOAC-associated intracerebral hemorrhage.
Transcript
Play full episode
